Trial finds Allegro test helps with cancer diagnosis
Maynard-based Allegro Diagnostics announced Wednesday that a clinical trial of its lung cancer test found that it improves the accuracy of diagnosis.
The BronchoGem uses gene expression coupled with a bronchoscopy (a procedure that allows doctors to look inside a patient’s lungs) to aid in the diagnosis of lung cancer. The test can help predict the absence of cancer in new lung masses, said Dr. Gerard Silvestri, a principal investigator in the study.
“The positive results … will soon enable us to offer the BronchoGem genomic test as part of our routine clinical testing for lung cancer,” Michael Webb, Allegro’s president and CEO, said in a statement. “A large percentage of bronchoscopies currently performed result in an inconclusive cancer diagnosis, leading to costly and risky invasive diagnostic and surgical procedures.”
The trial included 25 medical centers throughout the county with more than 1,000 patients enrolled. All of the patients are current or former smokers undergoing bronchoscopies for suspicion of lung cancer.
The results were consistent with preliminary data presented in October 2012.
The BronchoGem is on track to be Allegro’s first commercial product.
(Image credit: freedigitalphotos.net)
WBJ Web Partners
Most Recent
Most Recent
0 Comments